Complete Hearing Capability

What it is: Keeping the hearing you already have — protecting the cochlea’s delicate sensory cells and the nerve synapses behind them before noise, age, drugs, or disease can damage them. Why it matters: The cells that detect sound do not grow back on their own in humans, so every cell preserved is one that never has to be regrown or replaced. Prevention is the cheapest, surest hearing care there is, and it begins long before a person notices anything is wrong.

Preservation rests on the body’s own protective biology — the cochlea’s natural antioxidant defenses, the resilience of its hair cells, and the integrity of the ribbon synapses that connect inner hair cells to the auditory nerve. Research by Sharon Kujawa and Charles Liberman at Mass Eye and Ear revealed that even moderate noise — the kind that causes no lasting change in a hearing test — can permanently destroy these synapses, a condition called cochlear synaptopathy or “hidden hearing loss.” That discovery reframed preservation entirely: the goal is not just to avoid obvious deafness, but to protect the silent connections that let us understand speech in a noisy room. Emerging protective agents, otoprotectant drugs that shield hair cells during chemotherapy or loud exposure, and pharmacological approaches that calm the cochlea’s stress response are all being studied to extend the ear’s own resilience. This layer is the foundation of the whole system — the link that, kept strong, spares every other link downstream.

Noise that leaves a normal hearing test can still permanently sever the ear’s wiring. Sharon Kujawa and M. Charles Liberman at Mass Eye and Ear and Harvard Medical School exposed animals to moderate noise, found thresholds recovered fully, yet documented permanent loss of the ribbon synapses linking inner hair cells to the auditory nerve — the discovery of cochlear synaptopathy.

That “hidden hearing loss” explains why people struggle in noise with a clean audiogram. Liberman and Kujawa, examining human temporal bones, showed synapse and nerve-fiber counts decline steadily with age and noise long before threshold loss appears, reframing preservation around the silent connections that carry speech in a crowded room.

A proven drug already shields hair cells from a known poison. Investigators including teams at the University of Michigan Kresge Hearing Research Institute have advanced otoprotectants such as sodium thiosulfate, FDA-approved as Pedmark to prevent cisplatin chemotherapy-induced hearing loss in children — the first cleared medicine that preserves hearing during a toxic exposure.

Universal newborn screening makes preservation begin on day one. Programs built on the CDC’s Early Hearing Detection and Intervention model now screen roughly 98% of U.S. newborns within days of birth, catching loss early enough to protect language development before it is lost.

The cochlea’s own stress defenses are being recruited as medicine. Researchers at the NIDCD and academic otology labs are studying antioxidant and anti-inflammatory agents that calm the cochlea’s response to noise and ototoxic drugs, aiming to extend the ear’s natural resilience rather than work around its failure.

Research & institutions: Mass Eye and Ear; Harvard Medical School; Sharon Kujawa; M. Charles Liberman; Johns Hopkins; Stanford University; University of Michigan Kresge Hearing Research Institute; National Institute on Deafness and Other Communication Disorders (NIDCD); Centers for Disease Control and Prevention (EHDI); World Health Organization; National Institutes of Health.

What it is: Giving hearing back to people who have already lost it — through devices that bypass damage today, and through gene therapies that repair the molecular biology of hearing itself. Why it matters: For decades, restoration meant amplification or a cochlear implant: useful, but a workaround. The arrival of gene therapy that restores natural hearing changes the meaning of the word — restoration is becoming biological repair, not just a louder signal.

The breakthrough that proved restoration could mean true biological repair came from a single gene. Children born with mutations in the OTOF gene cannot make otoferlin, a protein their inner hair cells need to release sound signals to the nerve; the cells are alive but silent. In trials led by Zheng-Yi Chen at Mass Eye and Ear and Yilai Shu at Fudan University — with the first patient treated in December 2022 — a single injection delivered a working copy of OTOF on a harmless adeno-associated virus, restoring the body’s own hearing pathway. Deaf children went from no response to sound to recognizing voices, speaking in sentences, and even singing. In 2026 the FDA approved the first gene therapy for genetic hearing loss, marketed as Otarmeni, for OTOF-related deafness. Alongside this, refined cochlear implants and bone-conduction devices restore access to sound for those whose biology cannot yet be repaired — meaning restoration today spans a spectrum from cutting-edge biology to mature, reliable technology.

A single injection gave deaf children their own natural hearing. Zheng-Yi Chen at Mass Eye and Ear and Yilai Shu at Fudan University delivered a working copy of the OTOF gene on a harmless adeno-associated virus to children born without otoferlin; the first patient was treated in December 2022, and most regained measurable hearing.

The restored hearing was real enough for speech and song. In the Chen–Shu trials, children who began with no response to sound progressed within weeks to recognizing voices, and over follow-up developed spoken language and even sang — biological repair of the hearing pathway, not just amplification.

The result replicated across continents. Independent OTOF gene-therapy programs — including the AK-OTOF trial from Akouos and Eli Lilly with a child treated at major U.S. and European centers — reproduced restored hearing in additional children, confirming the effect was not a single-site anomaly.

Regulators have now cleared the approach. Building on this evidence, the first gene therapy for OTOF-related genetic deafness has moved through approval, turning a laboratory result into a prescribable treatment for an inherited cause of deafness.

Mature technology restores access for everyone gene therapy cannot yet reach. Refined multichannel cochlear implants and bone-conduction devices, with decades of NIDCD-supported evidence, reliably restore useful sound to people whose underlying biology cannot yet be repaired, so restoration spans frontier biology to dependable engineering.

Research & institutions: Mass Eye and Ear; Harvard Medical School; Zheng-Yi Chen; Fudan University; Yilai Shu; Akouos; Eli Lilly; Children’s Hospital of Philadelphia; U.S. Food and Drug Administration; National Institute on Deafness and Other Communication Disorders; National Institutes of Health; The Lancet.

What it is: Regrowing the two irreplaceable parts of the inner ear — the sensory hair cells that detect sound, and the nerve connections that carry it — using the body’s own developmental biology. Why it matters: Birds and fish naturally regrow hair cells; mammals lost that ability. Restoring it would address the root cause of most sensorineural hearing loss rather than working around it — turning permanent loss into something the ear can rebuild.

The cochlea holds the answer to its own repair. Hidden among its sensory cells are supporting cells that, during development, can become hair cells — and researchers have learned to reawaken that potential. Albert Edge at Mass Eye and Ear and Stefan Heller at Stanford showed that Lgr5-positive supporting cells can be coaxed to multiply and convert into new hair cells, driven by the master gene Atoh1, which is both necessary and sufficient to make a hair cell. Combinations of Atoh1 with Gfi1 and Pou4f3 reprogram adult supporting cells far more efficiently, and Wnt and Notch signaling control the switch. The nerve must regrow too: work building on Kujawa and Liberman’s synaptopathy findings showed that neurotrophin-3 (NT-3), the body’s own growth factor, can regenerate the ribbon synapses connecting hair cells to the auditory nerve after noise damage. Together, hair-cell and nerve regeneration aim to rebuild the cochlea’s sensory chain from its own cells — the most fundamental repair in the entire hearing system.

One master gene can turn a bystander cell into a sound sensor. Albert Edge at Mass Eye and Ear and Harvard Medical School showed that Atoh1 is both necessary and sufficient to drive a supporting cell to become a hair cell, identifying the central switch for regrowing the inner ear’s lost sensory cells.

The cochlea carries its own reservoir of replacement cells. Edge’s team demonstrated that Lgr5-positive supporting cells can be expanded and coaxed to convert into new hair cells, and that Wnt and Notch signaling control whether a supporting cell stays put or transforms.

Adult cells reprogram far better with a gene cocktail. Research combining Atoh1 with Gfi1 and Pou4f3 reprogrammed mature supporting cells into hair-cell-like cells far more efficiently than Atoh1 alone, a key step toward regeneration in the fully formed mammalian ear.

Stem-cell work rebuilt inner-ear hair cells in a dish. Stefan Heller at Stanford University generated functional hair-cell-like cells from stem cells and mapped the developmental signals that guide their formation, providing the blueprint for directing regeneration.

The nerve connection can be regrown after noise. Building on the synaptopathy discovery, Sharon Kujawa and M. Charles Liberman and collaborators showed that neurotrophin-3 (NT-3), the body’s own growth factor, regenerates the ribbon synapses between hair cells and the auditory nerve and recovers function after noise injury in animals.

Research & institutions: Mass Eye and Ear; Albert Edge; Harvard Medical School; Stanford University; Stefan Heller; Sharon Kujawa; M. Charles Liberman; University of Michigan Kresge Hearing Research Institute; Decibel Therapeutics; Frequency Therapeutics; National Institute on Deafness and Other Communication Disorders; National Institutes of Health.

What it is: Making sure the brain can still use restored hearing — rebuilding and retraining the auditory pathways and cortex so that a repaired ear produces real, meaningful sound. Why it matters: A perfectly restored cochlea is useless if the brain has forgotten how to listen. Hearing happens in the brain as much as the ear, and reconnecting the two is the layer that turns signal into understanding.

The brain is not a passive receiver — it is shaped by the sound it does or does not get. Andrej Kral and Anu Sharma showed that the auditory cortex has a critical period: a sensitive window, roughly the first three and a half years of life, during which it must receive sound input to wire itself for hearing. Deprive it too long and the cortex re-purposes itself for vision and touch, and later restoration delivers a weaker result — which is why early cochlear implantation in deaf children produces dramatically better speech and language than late implantation. But plasticity does not vanish entirely in adults; the brain retains the ability to relearn listening with the right input and training. This layer harnesses the brain’s own plasticity — through early intervention, auditory rehabilitation, and brain-aware device programming — so that whatever the ear delivers, whether from a regenerated cochlea or an implant, the brain can actually hear it. Without this link, every restorative breakthrough upstream falls short of its promise.

The listening brain has a hard deadline. Anu Sharma at the University of Colorado Boulder, using cortical evoked potentials in deaf children, identified a sensitive period of roughly the first three and a half years of life during which the auditory cortex must receive sound to wire itself normally for hearing.

Miss that window and the brain repurposes the hearing real estate. Andrej Kral at Hannover Medical School showed in congenitally deaf models that prolonged auditory deprivation lets the auditory cortex be recruited for vision and touch, degrading the benefit of any later restoration.

Timing of treatment predicts how well a child speaks. Sharma’s and Kral’s work explains why early cochlear implantation yields dramatically better speech and language outcomes than late implantation — the same device delivers far more when the brain is still primed to learn sound.

Adult brains still retain the capacity to relearn listening. Research on cortical plasticity in adult implant users shows the brain adapts to a new signal over weeks to months with structured input, so plasticity narrows with age but does not disappear.

Brain-aware rehabilitation is moving into the clinic. NIDCD-supported programs in auditory training and brain-informed device programming are being studied to harness that residual plasticity, so a regenerated or implanted ear meets a brain ready to interpret it.

Research & institutions: Anu Sharma; University of Colorado Boulder; Andrej Kral; Hannover Medical School; Johns Hopkins; House Ear Institute; University of Texas at Dallas; Mass Eye and Ear; National Institute on Deafness and Other Communication Disorders; National Institutes of Health.

What it is: Caring for the other half of the inner ear — the vestibular organs that keep you balanced and steady-eyed — and quieting the phantom sound of tinnitus that so often travels with hearing loss. Why it matters: The balance organs share the inner ear’s anatomy and its hair cells, so the same damage that steals hearing can rob steadiness and stable vision; and tinnitus, the brain’s response to lost input, affects tens of millions. A whole hearing system must address both.

The vestibular organs — the semicircular canals and otolith organs — use the same kind of hair cells as the cochlea, and the same regenerative biology applies. In 2024, researchers showed that inhibiting Notch signaling with the body’s own cellular reprogramming pathway regenerated vestibular hair cells and afferent neurons and restored the vestibulo-ocular reflex in animals — the first sign that lost balance can be rebuilt, not just compensated for. For people whose balance organs cannot be repaired, Charles Della Santina’s team at Johns Hopkins developed a multichannel vestibular implant that electrically restores the body’s balance reflexes, much as a cochlear implant restores hearing. Tinnitus is handled separately and gently in this system: Susan Shore at the University of Michigan traced much somatic tinnitus to the dorsal cochlear nucleus, where touch and sound signals collide, and built a bimodal neuromodulation device — sound paired with precisely timed electrical pulses — that retrains those circuits. A 2023 trial showed meaningful, lasting reduction in tinnitus loudness.

An implant can give back a sense of balance the way a cochlear implant gives back sound. Charles Della Santina at Johns Hopkins built a multichannel vestibular implant and, in results published in the New England Journal of Medicine in 2021, showed the first patients gained substantial improvements in posture, gait, and quality of life.

The benefit held even after decades of loss. Della Santina’s team reported that the device steadied balance and vision in patients whose vestibular function had been gone for more than twenty years, with effects that remained stable over years of use.

A precisely timed signal can quiet phantom ringing. Susan Shore at the University of Michigan traced much somatic tinnitus to the dorsal cochlear nucleus, where touch and sound signals converge, and built a bimodal device pairing sound with timed electrical pulses to retrain those circuits.

That approach reduced tinnitus in a controlled trial. Shore’s double-blind randomized trial of 99 participants with somatic tinnitus showed her bimodal neuromodulation produced meaningful, lasting reductions in tinnitus loudness and intrusiveness compared with control stimulation.

The balance organs share the cochlea’s regenerative biology. Because vestibular organs use the same kind of hair cells as the cochlea, regenerative tools transfer; in 2024 researchers reported that inhibiting Notch signaling regenerated vestibular hair cells and afferent neurons and restored the vestibulo-ocular reflex in animals.

Research & institutions: Johns Hopkins; Charles Della Santina; University of Michigan; Susan Shore; Auricle Inc.; Stanford University; Mass Eye and Ear; National Institute on Deafness and Other Communication Disorders; American Tinnitus Association; National Institutes of Health; New England Journal of Medicine.

What it is: Going beyond “normal” — tuning hearing for clarity in noise, and then sustaining the whole system’s health for decades so it never silently declines. Why it matters: Standard hearing tests miss the everyday struggle of understanding speech in a crowded room, and hearing loss creeps in so gradually that people lose years before they act. Optimization and lifelong resilience turn hearing care from a one-time fix into a continuous, measured practice.

Optimization starts where the standard hearing test ends. Much real-world difficulty — trouble following conversation in noise — comes from cochlear synaptopathy and central processing, not just threshold loss, so optimization targets the brain’s ability to separate speech from background using auditory training and AI-driven sound processing that learns a person’s listening environment. Sustaining the system over a lifetime draws on the body’s own resilience and on relentless measurement. The landmark ACHIEVE trial, led by Frank Lin and Josef Coresh at Johns Hopkins and published in 2023, found that treating hearing loss slowed cognitive decline by nearly half in older adults at higher risk — proving that protecting hearing protects the brain, and that lifelong hearing care is a longevity intervention. De Wet Swanepoel’s smartphone audiometry, adopted by the WHO as the hearWHO app, has screened hundreds of millions of people, and universal newborn hearing screening catches loss at birth. Together they make resilience a matter of continuous monitoring rather than belated rescue.

Treating hearing loss slowed cognitive decline by nearly half in those at highest risk. Frank Lin and Josef Coresh at Johns Hopkins led the ACHIEVE randomized trial, published in The Lancet in 2023, which found hearing intervention cut three-year cognitive decline by about 48% in older adults at elevated risk — establishing that hearing care is brain care.

A smartphone turned hearing screening into a global public-health tool. De Wet Swanepoel at the University of Pretoria developed validated digital speech-in-noise audiometry adopted by the World Health Organization as the hearWHO app, extending reliable screening to hundreds of millions of people without a clinic.

Universal newborn screening makes lifelong monitoring start at birth. Programs built on the CDC’s Early Hearing Detection and Intervention framework screen the vast majority of U.S. newborns within days, turning resilience into continuous tracking rather than belated rescue.

Real-world struggle in noise comes from more than threshold loss. Work by Kujawa, Liberman, and central-auditory researchers shows much difficulty following speech in a crowd stems from cochlear synaptopathy and central processing, defining the true target of optimization beyond a standard audiogram.

AI-driven processing is learning each listener’s world. Hearing-science and engineering groups are advancing machine-learning sound processing and auditory training that adapt to a person’s specific listening environments to separate speech from background noise more effectively over time.

Research & institutions: Johns Hopkins Bloomberg School of Public Health; Frank Lin; Josef Coresh; ACHIEVE study; University of Pretoria; De Wet Swanepoel; World Health Organization (hearWHO); Centers for Disease Control and Prevention (EHDI); National Institute on Aging; National Institutes of Health; The Lancet.

What it is: The connective layer that ties all the others together — an AI-supported, clinician-led plan that measures the whole hearing and balance system, sequences the right interventions in the right order, and keeps adjusting them over a lifetime. Why it matters: Ten capabilities delivered piecemeal will leave people falling through the gaps. Hearing is one connected system, so the care must be one connected plan — with a clinician, not an algorithm, holding final responsibility.

The hardest part of complete hearing capability is not any single therapy — it is orchestration. A person may need preservation now, regeneration later, brain retraining alongside a restored cochlea, balance care, and decade-by-decade monitoring, each interacting with the others. This layer uses the body’s own data — detailed maps of a person’s hearing, nerve function, balance, and brain response — combined with AI that can detect early decline, model how interventions interact, and flag the right moment to act. But the system is explicitly clinician-led: the AI surfaces evidence and options, and a trained audiologist or otologist makes the decisions and carries them out, exactly as the proven ACHIEVE model paired technology with skilled human care. Smartphone audiometry and teleaudiology extend that expert judgment to people far from major centers. This is the layer that refuses to pre-judge any one capability as more important than another — it treats preservation, restoration, regeneration, reconnection, rebalancing, and optimization as equal parts of a single coordinated design, sequenced around the individual person.

Coordinated, clinician-delivered hearing care produced a measurable brain benefit. Frank Lin and Josef Coresh at Johns Hopkins showed in the ACHIEVE trial (The Lancet, 2023) that a structured program of assessment, fitting, education, and counseling slowed cognitive decline by about 48% in higher-risk older adults — proof that orchestrated care, not a single device, drives the outcome.

The model worked because a skilled human led it. In ACHIEVE the technology was paired with a trained audiologist who made and adjusted the decisions, demonstrating that the gain came from clinician-led judgment wrapping the tools, not the tools alone.

Expert care can reach far beyond the major centers. De Wet Swanepoel at the University of Pretoria validated teleaudiology and smartphone-based screening adopted by the World Health Organization, showing clinician-guided assessment can extend to people far from specialist clinics.

The whole inner-ear system can already be measured as one. Otology programs at centers including Mass Eye and Ear and Johns Hopkins combine detailed maps of hearing thresholds, nerve function, balance, and cortical response, making it possible to detect early decline across the system before a person feels it.

The discoveries to be sequenced are themselves real. The capabilities this layer coordinates — from Zheng-Yi Chen’s OTOF gene therapy at Mass Eye and Ear to Albert Edge’s hair-cell regeneration and Susan Shore’s tinnitus neuromodulation — are documented results, so the unifying plan integrates proven and advancing science rather than speculation.

Research & institutions: Johns Hopkins; Frank Lin; Josef Coresh; ACHIEVE study; University of Pretoria; De Wet Swanepoel; World Health Organization; Mass Eye and Ear; Zheng-Yi Chen; Albert Edge; Susan Shore; American Academy of Audiology; National Institute on Deafness and Other Communication Disorders; National Institutes of Health.